Coronavirus infection is a serious health problem awaiting an effective vaccine and/or antiviral treatment. The major complication of coronavirus disease 2019 (COVID-19), the Acute Respiratory Distress syndrome (ARDS), is due to a variety of mechanisms including cytokine storm, dysregulation of the renin-angiotensin system, neutrophil activation and increased (micro)coagulation. Based on many preclinical studies and observational data in humans, ARDS may be aggravated by vitamin D deficiency and tapered down by activation of the vitamin D receptor. Several randomized clinical trials using either oral vitamin D or oral Calcifediol (25OHD) are ongoing. Based on a pilot study, oral calcifediol may be the most promising approach. These studies are expected to provide guidelines within a few months.
Keywords: 1α, 25(OH)2D or 1α, 25-dihydroxyvitamin D or calcitriol; Acute respiratory distress syndrome (ARDS); Calcifediol or 25-hydroxyvitamin D3; Corona virus; Cytokine storm; Hypercoagulability; Lung diseases; Renin-angiotensin system; SARS-CoV-2; Vitamin D, vitamin D3 or cholecalciferol.
Copyright © 2020 Elsevier Ltd. All rights reserved.